Oasmia Pharma (OASM) Enters New Shares Private Placement
- Indexes hit record highs as Trump rally continues
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- Lower for longer, ECB scales back asset buys
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Oil rises above $50 on renewed hopes for output cuts
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Oasmia Pharma (Nasdaq: OASM) hereby announces the launch of a private placement of new shares ("New Shares") through a directed new share issue to international institutional investors and qualified investors in Sweden (the "Private Placement").
The price of the New Shares will be determined through an accelerated book building procedure. The book building will begin on October 22, 2016.
The Company intends to use the proceeds from the Private Placement to strengthen the working capital as well as finance the continued operations and further development of additional human and veterinary products based on the XR17 technology.
The Private Placement is subject to, inter alia, a resolution by the Board of Directors of Oasmia, pursuant to the authorization granted by the annual general meeting held on September 26, 2016, to issue New Shares following the completion of the Private Placement book building procedure. The reason for deviating from the shareholders' preferential rights by conducting a directed new share issue is to broaden the shareholder base and that the costs of the procedure and the timing collectively and with sufficient strength indicate that it is in the Company's and thus the shareholders' interest that the issue is made with deviation from the shareholders' preferential rights.
Notes to editors:
About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
IMPORTANT INFORMATION Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ), Stockholm Corporate Finance AB nor anyone else.
Julian Aleksov, Executive Chairman Tel: +46 18 50 54 40 E-mail: firstname.lastname@example.org
Source: Oasmia Pharmaceutical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LinkedIn (LNKD), Microsoft (MSFT) Deal Closes
- Recro Pharma (REPH) Plans Offering of Common Stock
- Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!